In The News: Department of Brain Health
Most ARIA cases are mild, but some have been fatal
Recently approved disease-modifying treatments for Alzheimer's disease have created a sudden demand, but these and other drugs in the pipeline are not for all patients with clinical Alzheimer's symptoms, experts said.
Looking ahead to 2024 and beyond: "There is so much more to be done"
Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.
After decades of failed trials, ineffective drugs and billions of dollars spent, a new frontier of shots offer a glimmer of hope for current and future sufferers of the cruel condition that affects 5.8million Americans.
The positive results are expected to form the basis for further development of Lomecel-B as a potential treatment for mild AD
Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial
Neurologists at the biggest Alzheimer's research meeting in the US experienced something this week they hadn't in years: optimism.
Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.
In 2014 neurologist Jeffrey L. Cummings, MD, startled the Alzheimer’s disease research world with a paper that laid bare the alarmingly high failure rate of Alzheimer’s disease therapies in development.
The FDA was busy in September 2023, making a number of decisions on potential new therapeutic agents including granting approvals, updating a label, issuing complete response letters, granting a clearance, and lifting a clinical trial hold, among other actions.
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.